SINCO PHARMACEUTICALS HOLDINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.25 HKD | -1.96% |
|
+2.04% | +4.17% |
| Sales 2022 | 2.27B 313M 2.45B 26.15B | Sales 2023 | 2.54B 351M 2.74B 29.24B | Capitalization | 443M 61.2M 479M 5.1B |
|---|---|---|---|---|---|
| Net income 2022 | 69M 9.52M 74.53M 794M | Net income 2023 | 42M 5.8M 45.36M 483M | EV / Sales 2022 | 0.15 x |
| Net cash position 2022 | 137M 18.87M 148M 1.57B | Net cash position 2023 | 187M 25.74M 201M 2.15B | EV / Sales 2023 | 0.1 x |
| P/E ratio 2022 |
6.88
x | P/E ratio 2023 |
10.5
x | Employees | 278 |
| Yield 2022 |
3.7% | Yield 2023 |
1.62% | Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.96% | ||
| 1 week | +2.04% | ||
| Current month | -3.85% | ||
| 1 month | -3.85% | ||
| 3 months | -1.96% | ||
| 6 months | +2.04% | ||
| Current year | +4.17% |
1 week
0.22
0.28
1 month
0.220.28
Current year
0.210.30
1 year
0.210.42
3 years
0.182.32
5 years
0.162.32
10 years
0.152.32
| Managers | Title | Age | Since |
|---|---|---|---|
Min Jin
CEO | Chief Executive Officer | 47 | 06/20/06 |
Xiang Bin Huang
FOU | Founder | 59 | 01/11/01 |
Yi Fan Li
DFI | Director of Finance/CFO | 45 | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ying Kit Lau
BRD | Director/Board Member | 50 | 08/18/08 |
Wen Fang Liu
BRD | Director/Board Member | 87 | 01/16/01 |
Xiang Bin Huang
FOU | Founder | 59 | 01/11/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 0.25 | -1.96% | 356 000 |
| 26/24/26 | 0.255 | +2.00% | 412,000 |
| 25/24/25 | 0.25 | 0.00% | 256,000 |
| 24/24/24 | 0.25 | +2.04% | 128,000 |
| 23/24/23 | 0.245 | 0.00% | 0 |
Delayed Quote Hong Kong S.E., April 29, 2024 at 01:38 pm IST
More quotes
Sinco Pharmaceuticals Holdings Limited operates as one provider of marketing, promotion and channel management (MPCM) services in the People's Republic of China (PRC) pharmaceutical industry. It provides its integrated MPCM services to small- and medium-sized overseas pharmaceutical manufacturers that do not possess independent marketing and promotion capabilities in China. Its major product is human albumin solution, a human albumin product manufactured by Octapharma, which is used to remedy hypovolemia and hypovolemic shock, abnormally high intracranial pressure, edema and ascites, and to prevent and cure hypoalbuminemia and neonatal hyper-bilirubinemia. In addition, its products include axetine, medocef, esafosfina, tad and taurolite.
Sector
Pharmaceuticals
Calendar
29/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +4.17% | 66.22M | |
| +17.35% | 71.39B | |
| +2.39% | 25.1B | |
| -1.22% | 8.59B | |
| +6.69% | 8.19B | |
| -20.96% | 7.91B | |
| -0.24% | 4.54B | |
| +17.12% | 4.31B | |
| -2.61% | 3.86B | |
| +22.08% | 3.64B |
- Stock Market
- Equities
- 6833 Stock
